Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
BRAF Antibody
Purified Mouse Monoclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, IHC, E |
|---|---|
| Primary Accession | P15056 |
| Reactivity | Human |
| Host | Mouse |
| Clonality | Monoclonal |
| Clone Names | 1H12F1; 1H12G10; 1F12F11C9 |
| Isotype | IgG1 |
| Calculated MW | 84437 Da |
| Description | BRAF(V-raf murine sarcoma viral oncogene homolog B1 ) is the main effectors recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway. B-Raf contains three consensus Akt phosphorylationsites (Ser364, Ser428, and Thr439).B-Raf is a key regulatory molecule of the mitogen-activated protein kinase kinase (MEK),it has a long amino-terminal region,the region is essential for homo-dimerization of B-Raf and hetero-dimerization of B-Raf and c-Raf at the plasma membrane, followed by phosphorylation of Thr118 in the amino-terminal B-Raf-specific region. Notably, in calcium ionophore-stimulated HeLa cells, B-Raf could propagate signals to MEK under the basal level of GTP-Ras. Expression of Raf-B is highly restricted with highestlevels in the cerebrum and testes and defects in braf are involved in a wide range of cancers.The BRAF gene mutation is frequently detected in papillary thyroid carcinoma,melanocytic nevi,primary cutaneous melanomas and colorectal cancers. |
| Immunogen | Purified recombinant fragment of BRAF expressed in E. Coli. |
| Formulation | Ascitic fluid containing 0.03% sodium azide. |
| Gene ID | 673 |
|---|---|
| Other Names | Serine/threonine-protein kinase B-raf, 2.7.11.1, Proto-oncogene B-Raf, p94, v-Raf murine sarcoma viral oncogene homolog B1, BRAF, BRAF1, RAFB1 |
| Dilution | WB~~1/500 - 1/2000 IHC~~1/200 - 1/1000 IF~~1:200~1000. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | BRAF Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | BRAF (HGNC:1097) |
|---|---|
| Synonyms | BRAF1, RAFB1 |
| Function | Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179). |
| Cellular Location | Nucleus. Cytoplasm. Cell membrane. Note=Colocalizes with RGS14 and RAF1 in both the cytoplasm and membranes. |
| Tissue Location | Brain and testis. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
References
1. Rapp, U.R.,et al.1983.Proc. Natl.Acad.Sci.USA.80:4218-4222. 2. Kim J,Giuliano AE,Turner RR.2006.Ann Surg.Nov, 244(5): 799-804. 3. Fullen DR, Poynter JN, Lowe L,2006.Mod Pathol. 19(10): 1324-1332. 4. Terai K, Matsuda M.2006.MBO J.25(15):3556-3564. 5. Noda H,Kato Y,Yoshikawa H,2006.J Exp Clin Cancer Res. 25(2):235-242.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
